Fifth Third Bancorp lowered its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 4.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 500,256 shares of the conglomerate's stock after selling 22,270 shares during the quarter. Fifth Third Bancorp owned approximately 0.07% of Danaher worth $102,552,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Zhang Financial LLC increased its position in Danaher by 3.6% in the 1st quarter. Zhang Financial LLC now owns 1,774 shares of the conglomerate's stock valued at $364,000 after acquiring an additional 62 shares in the last quarter. Alpha Omega Wealth Management LLC grew its position in shares of Danaher by 1.6% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 14,646 shares of the conglomerate's stock worth $3,002,000 after buying an additional 229 shares during the period. McKinley Carter Wealth Services Inc. grew its position in shares of Danaher by 2.8% during the 1st quarter. McKinley Carter Wealth Services Inc. now owns 3,004 shares of the conglomerate's stock worth $616,000 after buying an additional 81 shares during the period. Curbstone Financial Management Corp grew its position in shares of Danaher by 11.2% during the 1st quarter. Curbstone Financial Management Corp now owns 3,966 shares of the conglomerate's stock worth $813,000 after buying an additional 400 shares during the period. Finally, CX Institutional grew its position in shares of Danaher by 11.2% during the 1st quarter. CX Institutional now owns 3,304 shares of the conglomerate's stock worth $677,000 after buying an additional 334 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.
Insider Transactions at Danaher
In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.
Danaher Price Performance
DHR traded up $0.13 on Thursday, hitting $204.85. 3,661,150 shares of the stock were exchanged, compared to its average volume of 3,495,448. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The business has a 50-day moving average of $191.79 and a two-hundred day moving average of $211.67. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a market capitalization of $146.60 billion, a price-to-earnings ratio of 38.80, a PEG ratio of 2.66 and a beta of 0.77.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher's dividend payout ratio (DPR) is currently 24.85%.
Analyst Ratings Changes
Several brokerages have recently commented on DHR. Robert W. Baird lowered their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Wolfe Research lowered their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research report on Monday, April 7th. Wells Fargo & Company lowered their price target on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 23rd. Royal Bank of Canada reissued an "outperform" rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, April 23rd. Finally, HSBC reduced their price objective on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average price target of $248.17.
View Our Latest Report on Danaher
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
